Undisclosed tumor-infiltrating Treg surface molecule

The term "Undisclosed tumor-infiltrating Treg surface molecule" is a placeholder designation frequently used in the biotechnology and pharmaceutical industry (e.g., by companies like Egle Therapeutics and Kainova Therapeutics) to refer to proprietary therapeutic targets selectively expressed on regulatory T cells (Tregs) within the tumor microenvironment (TME) [1, 7]. These targets are highly sought after because they allow for the specific depletion or functional inhibition of immunosuppressive Tregs that facilitate tumor immune evasion, while ideally sparing peripheral Tregs to minimize the risk of systemic autoimmunity [2, 5]. The most prominent specific molecule currently fitting this description in clinical development is Chemokine receptor 8 (CCR8), which is significantly upregulated on tumor-infiltrating Tregs compared to those in healthy tissues or circulation [3, 6]. Other potential targets in this category include Tumor necrosis factor receptor 2 (TNFR2) and Glycoprotein A repetitions predominant (GARP) [2]. Therapeutic strategies typically involve monoclonal antibodies engineered to induce antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP) to selectively clear these suppressive cells from the tumor site [3, 7].

Other names

Undisclosed Treg targetTumor-selective regulatory T cell surface proteinNovel Treg-specific surface molecule

Selective depletion of tumor-infiltrating regulatory T cells (Tregs) via antibody-dependent cellular cytotoxicity (ADCC) or inhibition of Treg-mediated immunosuppressive signaling.